IMC 002 - Suzhou Immunofoco Biotechnology
Alternative Names: Anti-Claudin18.2-CAR-T cell therapy - Suzhou Immunofoco Biotechnology; Claudin 18.2 CAR-T cell therapy - Suzhou Immunofoco Biotechnology; IMC-002 - Suzhou Immunofoco BiotechnologyLatest Information Update: 06 Jun 2024
At a glance
- Originator Suzhou Immunofoco Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Adenocarcinoma; Digestive system neoplasms; Gastric cancer; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 01 Jun 2024 Efficacy, adverse events and pharmacodyanamic data from a phase I trial in Gastric cancer released by Immunofoco Biotech
- 01 Jun 2024 Pharmacodynamics data from a preclinical trial in Solid tumours released by Immunofoco Biotech
- 31 May 2024 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)